2Bianchi S, Bigazzi R, Canpese V. Microalbuminuria in essential hypertension[J]. Am J Kidney Dis, 1999,34:973-995 .
3The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-depentment diabetes mellitus [J]. N Engl J Med, 1993, 328: 329-342.
4Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes [J]. Lancet, 1998, 352: 837-845.
5William IS. Lipotoxicity and glucotoxicity in type 2 diabetes [J]. Post- graduate Medicine, 2001,109:55-68.
6Dominguec JH, Tang N, Xu W, et al. Studies of renal injury Ⅲ: lipid- induced nephropathy in type Ⅱ diabetes [J]. Kidney Int, 2000,57:92- 104.
7Hirao T. Lipoprotein abnormalities in diabetic nephropathy[J]. Kidney Int Suppl Jul, 1999, 71:22-24.
9Kobayashi N,Horinaka S, Mita S,et al.Critical role of Rhokinase pathway for cardiac performance and remodeling in failing rat hearts[J].Cardiovasc Res, 2002, 55:757-767.
1Fago AB. Mesangial matrix modulation and glomerulosclerosis. Exp Nephrol, 1999, 7: 147-159.
2Nogaki F, Muso E, Yashiro M, et al. Direct inhibitory effects of simvastatin on matrix accumulation in cultured murine mesangial cells. Kidney Int, 1999, 56 Suppl 71: S198-S201.
3Baricos WH, Cortez SL, Deboisblanc, et al. Transforming growth factor-β is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol, 1999, 10:790-795.
4Nishimura M, Tanaka T, Yasuda T, et al. Collagen secretion and growth of mesangial cells require geranylgeranylpyrophosphate.Kidney Int, 1999, 55: 520-528.
5Schnaper HW. Balance between matrix synthesis and degradation:a determinant of glomerulosclerosis. Pediatr Nephrol, 1995, 9:104-111.
6Oda H, Keane WF. Recent advances in statins and the kidney.Kidney Int, 1999, 56 Suppl 71: S2-S5.
7李中言，中华心血管病杂志，1996年，24卷，73页
8Han D C，Kidney Int，1993年，44卷，1181页
9.中药新药临床研究指导原则.[S].中华人民共和国卫生部制定发布,1993.158.
10Fukuzawa Y,Watanabe Y,Inaguna D,et al.Evaluation of glomerular lesion and abnormal urinary findings in OLETF rats resulting from a long-term diabetic state.J Lab Clin Med,1996,128:568-578.
8Alderson P, Green S, Higgins JPT. Cochrane Reviewers'Handbook 4.2.2[updated March 2004]. In: The Cochrane Library, Issue 1,2004.
9Mitch WE. Treating diabetic nephropathy--are there only economic issues? New England Journal of Medicine, 2004, 351 ( 19): 1934-1936.
10Hung CC, Yinn YG, Shyi TS, et al. Insulin and heparin suppress superoxide production in diabetic rat glomeruli stimulated with lowdensity lipoprotein. Kidney, 2001, 59(suppl): 124.
